Floatz logo

Tilmanocept

Rhabdomyosarcoma

Cardinal Health 414, LLCOtherPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
73/ 100

Competitive context

59 Active assets in the Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Eisai Inc.
Phase 2BBB
Ipilimumab
Children's National Research Institute
Phase 2BB
CALCIUM PHOSPHATE
Children's Oncology Group
Phase 3BB
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Tilmanocept is also rated in:

melanomaDormant
B
Indicative ·
61 / 100
View asset →
Sentinel Lymph Node BiopsyDormant
B
Indicative ·
56 / 100
View asset →
Sentinel Lymph NodeDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →